Clinical Trials Logo

Unresectable clinical trials

View clinical trials related to Unresectable.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01318642 Terminated - Clinical trials for Adenocarcinoma of the Pancreas

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

Start date: May 2012
Phase: Phase 2
Study type: Interventional

This study is a phase 2, multicenter, randomized, double-blind, active placebo-controlled trial of AMG 479 or placebo in combination with gemcitabine as first-line therapy for locally advanced unresectable adenocarinoma of the pancreas. Approximately 150 subjects will be randomized in a 1:1 ratio to AMG 479 and gemcitabine, or gemcitabine and placebo. Randomization will be stratified by ECOG (0 or 1). Gemcitabine will be given on days 1, 8, and 15, followed by AMG 479 on days 1 and 15 of every 28 day cycle. Treatment will continue until radiographic disease progression, unacceptable toxicity, withdrawal of consent, or start of a new anti-cancer therapy.